Mount Sinai Medical Center

BPGbio Announces First Patients Dosed in Phase 2 Trial of AI-Developed BPM 31510 for Glioblastoma Multiforme

Retrieved on: 
Martedì, Giugno 6, 2023
Research, Technology, Neurology, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Survival rate, Radiation, Therapy, GBM, Survival, Glioblastoma, Brain, BPM, Patient, Division, Stanford University School of Medicine, TME, United Kingdom, Diagnosis, Mount Sinai Medical Center, Cedars-Sinai Medical Center, Rare, Tumor microenvironment, Safety, Medical imaging, Pharmaceutical industry, MD

BPGbio, Inc ., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced that patients have been initially dosed in its Phase 2 trial for BPM 31510 for Glioblastoma Multiforme (GBM), a fast-growing and aggressive form of brain cancer.

Key Points: 
  • BPGbio, Inc ., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced that patients have been initially dosed in its Phase 2 trial for BPM 31510 for Glioblastoma Multiforme (GBM), a fast-growing and aggressive form of brain cancer.
  • BPM 31510 for GBM is one of the three oncology drug assets in clinical phase that BPGbio developed on its AI-driven Interrogative Biology® platform .
  • A Phase 1 trial in advanced, refractory GBM patients completed at Stanford Medicine demonstrated a favorable safety profile of BPM 31510, supporting Phase 2 trial advancement.
  • Leveraging the results from the phase 1 clinical trial, we are looking forward to further advance our discoveries using neoadjuvant BPM 31510 in phase 2,” said Seema Nagpal, MD.

Award-Winning Retina Specialist Joins Leading Retina Practice in New York

Retrieved on: 
Martedì, Maggio 23, 2023
Retina, University, Manhattan Eye, Ear and Throat Hospital, AMD, Physician, Consultant, Castle Connolly Medical, Alpha Omega Alpha, Patient, AOA, Medical missions, North Shore University Hospital, Patient choice, Lenox Hill Hospital, Columbia University Vagelos College of Physicians and Surgeons, Mount Sinai Medical Center, VRC, Hospital, Risk, Surgeon, Diabetic retinopathy, Columbia University College of Dental Medicine, Ear, Retinal scan, Nursing, Ophthalmology

NEW YORK, May 23, 2023 /PRNewswire-PRWeb/ -- Vitreoretinal Consultants of NY (VRC) is pleased to announce that Dr. Jeffrey C. Paccione, an award-winning retina specialist and surgeon, has joined their retina practice, making it possible for even more patients across the Tri-State Area to access advanced vision care. Dr. Paccione will continue to provide care for his existing patients from VRC's newly opened offices in Manhattan and New Rochelle, and he will also begin seeing patients at VRC's existing locations in Elmhurst and Rockland.

Key Points: 
  • "It's an honor to help patients who are at risk of losing their vision or who have already lost it," said Dr. Paccione.
  • Together, we will be able to provide even more patients in New York with the vision care they need."
  • Dr. Paccione is specially trained to treat the full spectrum of conditions affecting the retina, macula, and vitreous.
  • He earned his medical degree with Alpha Omega Alpha (AOA) medical honors from Columbia University College of Physicians and Surgeons in New York.

Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role

Retrieved on: 
Lunedì, Maggio 8, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Rubius, Inflammation, Erna, Amgen, Gilead Sciences, Pediatric Hematology and Oncology, Drug development, University, Onyx, El Rubius, Cancer, Autoimmunity, RNA, Mount Sinai Medical Center, Onyx Pharmaceuticals, Haematopoietic system, Organization, Chemistry, Senior, Investigational New Drug, Patient, Biology, R, Therapy, Pharmaceutical industry, Oncology, Hematology, Dermatology, Medicine

Incyte (Nasdaq:INCY) today announced the creation of a new leadership role, appointing Pablo J. Cagnoni, M.D.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced the creation of a new leadership role, appointing Pablo J. Cagnoni, M.D.
  • President and Head of Research & Development (R&D) effective June 5, 2023.
  • “This newly created role integrates chemistry, biology and development with the goal of maximizing the impact of our portfolio and accelerating our innovative pipeline,” said Hervé Hoppenot, Chief Executive Officer, Incyte.
  • “Incyte has a strong foundation of bringing first-in-class treatments to patients and I am honored to join the organization,” said Dr. Cagnoni.

Tampa General Hospital Names New Senior Vice President of Surgical Services

Retrieved on: 
Venerdì, Maggio 5, 2023
Perioperative, Iona University, Association of periOperative Registered Nurses, Nursing, Kate, Research, BSN, Greenwich Hospital, Mount Sinai Medical Center, White Plains Hospital, Iona, AORN, Patient, Tampa General Hospital, TGH, Yale New Haven Health System, Westchester Square Medical Center, RN, Ulrich, Duke University Health System, Science

TAMPA, Fla., May 5, 2023 /PRNewswire/ -- Tampa General Hospital (TGH) has named Kathleen Ulrich, MS, BSN, RN, NEA-BC, to the hospital's leadership team as senior vice president of Surgical Services.

Key Points: 
  • TAMPA, Fla., May 5, 2023 /PRNewswire/ -- Tampa General Hospital (TGH) has named Kathleen Ulrich, MS, BSN, RN, NEA-BC, to the hospital's leadership team as senior vice president of Surgical Services.
  • Ulrich is an experienced health care professional who brings almost 30 years of nursing expertise to Tampa General.
  • Most recently, she was the assistant vice president of Nursing Perioperative Services at Duke University Health System in Durham, North Carolina.
  • "As an academic medical center, Tampa General provides patients with innovative and advanced surgical procedures every day.

Dr. Lawrence Kirschenbaum Joins Physician Partners of America- West Palm Beach, FL

Retrieved on: 
Venerdì, Marzo 31, 2023
PALM, Pain management, University, Anesthesiology, Interventional pain management, Long Island, Partner, American Society of Interventional Pain Physicians, Mount Sinai Medical Center, Suite, Long Island Jewish Medical Center, Patient, Bridgeport Hospital, Sentara Northern Virginia Medical Center, Nursing

WEST PALM BEACH, Fla., March 31, 2023 /PRNewswire-PRWeb/ -- Physician Partners of America (PPOA) is pleased to announce that interventional pain management specialist Lawrence Kirschenbaum, M.D., has joined the company's West Palm Beach, Florida pain management practice. He began seeing patients on March 6 at the office, located at 6910 S. Dixie Hwy, Suite 102, West Palm Beach, FL 33405.

Key Points: 
  • WEST PALM BEACH, Fla., March 31, 2023 /PRNewswire-PRWeb/ -- Physician Partners of America (PPOA) is pleased to announce that interventional pain management specialist Lawrence Kirschenbaum, M.D., has joined the company's West Palm Beach, Florida pain management practice.
  • He began seeing patients on March 6 at the office, located at 6910 S. Dixie Hwy, Suite 102, West Palm Beach, FL 33405.
  • Dr. Lawrence Kirschenbaum, is a notably experienced, board-certified, fellowship trained Interventional Pain Management Physician.
  • In addition to his practice of interventional pain management, Dr. Kirschenbaum remains an Associate Clinical Professor at the Yale University School of Medicine.

CDC Warns Deadly Drug Resistant Candida auris Spreading Rapidly Across US

Retrieved on: 
Mercoledì, Marzo 22, 2023
Technology, Infectious Diseases, Hospitals, HVAC, Health Technology, Manufacturing, Software, Health, IOT (Internet of Things), Wi-Fi, Internet, Hospital, Candida auris, NASA, Patient, Collection, Length of stay, American College, News, Disease, Atmosphere, ISO, Centers for Disease Control and Prevention, MERSA, Research, Infection, Hospital-acquired infection, Sepsis, U.S. News & World Report, CDC, Ambulatory care, EPA, LED, Mount Sinai Medical Center, COVID 19, Bacteria, FDA, Death, NIH, AR, Skin, Microbiology, Auris, Trauma Center, Preventive healthcare, Methicillin-resistant Staphylococcus aureus, Health care, Trauma center, MRSA, UVC, IOT, Mortality, Mount Sinai Health System, Puro, Central nervous system, Icahn School of Medicine at Mount Sinai, COVID, Fungal infection, RF, Pernicious, Vaccine, Sewage treatment, UV, Candidiasis

Testing determined that Puro UV disinfecting fixtures are effective at killing the C. auris fungus.

Key Points: 
  • Testing determined that Puro UV disinfecting fixtures are effective at killing the C. auris fungus.
  • Applied UV‘s patented LumiCide Surface and Drain UVC Disinfecting Systems is currently installed within the world renowned Mt.
  • Candida auris is an emerging fungal pathogen that presents a serious global health threat.
  • Many HAI’s are caused by the most urgent and serious antibiotic-resistant (AR) bacteria and my lead to sepsis or death.

Cagent Vascular announces superior lumen gain, greater volumetric blood flow using Serration Angioplasty: A sub-analysis of the PRELUDE BTK study

Retrieved on: 
Martedì, Gennaio 31, 2023
Health, Surgery, Health Technology, Clinical Trials, General Health, Biotechnology, Angioplasty, Physician, Journal, CLTI, Biomedicine, Patient, Dean (education), Biomedical engineering, Poiseuille, Amputation, Mount Sinai Medical Center, Death, PAD, Wound healing, UC, Peripheral artery disease, Serration, BTK, Quality of life, POBA, University of California, Irvine, Medical device, Fernand Serrane, Research

Cagent Vascular, the exclusive developer of Serration Angioplasty (Serranator®), announced the results of a comparative sub-analysis of the PRELUDE-Below-the-Knee (BTK) study versus Plain Old Balloon Angioplasty (POBA).

Key Points: 
  • Cagent Vascular, the exclusive developer of Serration Angioplasty (Serranator®), announced the results of a comparative sub-analysis of the PRELUDE-Below-the-Knee (BTK) study versus Plain Old Balloon Angioplasty (POBA).
  • The Serranator-treated lesions had an average final residual stenosis of 17.2 +/- (8.2%) versus 33.7 +/- (15.7%) in the POBA group.
  • The average balloon inflation pressure was 5 ATM in the Serranator group versus 9 ATM in the conventional balloon angioplasty group.
  • In these cases, our goal is to restore sufficient blood flow to allow a patient’s wound to heal, without leaving anything behind.

Schwarzman Animal Medical Center Appoints Helen Irving, RN, MBA, President and Chief Executive Officer

Retrieved on: 
Mercoledì, Gennaio 25, 2023
Fairleigh Dickinson University, National Cancer Center, United Kingdom, Health, MBA, Health administration, AMC, Hospital, RN, NewYork-Presbyterian Hospital, Pet, NYIT, Stephen, Organization, Mount Sinai Medical Center, Family, Trustee, Nursing, Tobacco

NEW YORK, Jan. 25, 2023 /PRNewswire/ -- The Stephen & Christine Schwarzman Animal Medical Center Board of Trustees has announced Helen Irving, RN, MBA, as its incoming President and Chief Executive Officer. Ms. Irving joins AMC, the largest non-profit animal hospital in the world, on January 30, 2023, during a pivotal time for the 113-year-old Upper East Side institution. The hospital is currently undergoing a $100 Million expansion and modernization project to accommodate unprecedented demand for its veterinary care. 

Key Points: 
  • The Seasoned Healthcare Executive Brings 30+ Years of Clinical, Administrative, and Operations Experience
    NEW YORK, Jan. 25, 2023 /PRNewswire/ -- The Stephen & Christine Schwarzman Animal Medical Center Board of Trustees has announced Helen Irving, RN, MBA, as its incoming President and Chief Executive Officer.
  • The hospital is currently undergoing a $100 Million expansion and modernization project to accommodate unprecedented demand for its veterinary care.
  • An accomplished leader and healthcare executive, Helen Irving has devoted her 30-year career to operational excellence in the delivery of healthcare services.
  • "Leading the Schwarzman Animal Medical Center is such an exciting opportunity given my deep roots in New York's healthcare system," said Ms. Irving.

Orchestra BioMed Strengthens Senior Leadership Team

Retrieved on: 
Martedì, Febbraio 7, 2023
Actinium, Solaris, Electrophysiology, HOPE, New Jersey Institute of Technology, Chemical engineering, Science, SAB, R, Pharmaceutical Development and Technology, St. Jude Medical, Divisional Railway Hospital, Golden Rock, Technology transfer, Cordis, Quality assurance, Research, Biomedical engineering, Head, Medical Affairs Bureau, Patient, Partnership, SVP, Medicine, Senior, Arrhythmia, Formulation, Mount Sinai Medical Center, Johnson & Johnson, Orchestra, Atrial fibrillation, Engineering, Pfizer, Management, Fine chemical, Innovation, Quality, Leonardo S.p.A.

NEW HOPE, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the addition of several highly accomplished industry veterans to its senior leadership team. Avi Fischer, M.D., joins as Senior Vice President (SVP), Medical Affairs and Innovation, and J.C. Simeon assumes the role of SVP, Quality. George Papandreou, Ph.D., has been promoted to General Manager and SVP of Focal Therapies (previously SVP, Quality) and Kunal Faldu has been promoted to Vice President (VP) of Pharmaceutical Development (previously Senior Director, Formulation Development).

Key Points: 
  • “We are very pleased to have several outstanding industry leaders join and assume key roles on our leadership team.
  • George and Kunal have proven themselves as important leaders within our growing organization,” said Darren R. Sherman, President, Chief Operating Officer and Co-Founder of Orchestra BioMed.
  • Prior to joining Orchestra BioMed, he held senior roles at C.R.
  • Before joining Orchestra BioMed, Mr. Faldu worked for Solaris Pharma Corporation as Senior Director, Program Management and Manufacturing.

Sun Communities, Inc. Appoints Jeff Blau to Its Board of Directors

Retrieved on: 
Mercoledì, Gennaio 25, 2023
The Related Companies, Wharton School of the University of Pennsylvania, Equity, Critical Ecosystem Partnership Fund, Lincoln Center, Central Park Conservancy, School, Sun Communities, NYSE, Master of Business Administration, Diversity, Related, Business administration, Trinity School, ED, SoulCycle, Wendell Pritchett, SUI, University, Robin Hood Foundation, The Real Estate Roundtable, Mount Sinai Medical Center, Mount Sinai Medical Center (Miami), Chair, Management

Southfield, MI, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Sun Communities, Inc. (NYSE: SUI) (the “Company” and “Sun”), announced, effective today, that, Mr. Jeff Blau has joined the Company’s Board of Directors (the “Board”) as an independent director.

Key Points: 
  • Southfield, MI, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Sun Communities, Inc. (NYSE: SUI) (the “Company” and “Sun”), announced, effective today, that, Mr. Jeff Blau has joined the Company’s Board of Directors (the “Board”) as an independent director.
  • Mr. Blau is Chief Executive Officer and a partner of Related Companies, a fully-integrated real estate firm based in New York, NY.
  • For over 33 years, he has directed and overseen new developments totaling over $60 billion in virtually every sector of the real estate industry.
  • “Sun is very pleased to welcome Jeff to our Board,” said Gary Shiffman, Chief Executive Officer.